In patients with previously treated advanced NSCLC, the POPLAR and OAK randomized clinical trials established the superiority of atezolizumab, a PD-L1 inhibitor, over standard chemotherapy with docetaxel, leading to the approval of the PD-L1 inhibitor as a second-line treatment option after progression to first-line platinum-based chemotherapy, regardless of PD-L1 expression levels [124,125]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.